Problems Related To Software, Heparin Help Push Recalls To All-Time High
This article was originally published in The Gray Sheet
Executive SummaryThe number of recalled medical devices skyrocketed last year to its highest point ever, spurred on by a large volume of recalls related to software and devices containing tainted heparin
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.